Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VG161 in Advanced Bone and Soft Tissue Sarcoma
NCT06126510Phase 2Recruiting
- Sponsor
- Virogin Biotech
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of VG161 in bone sarcoma, soft tissue sarcoma (STS), sponsored by Virogin Biotech. Started Jul 2023; status: recruiting.
02
Drugs
VG161
03
Conditions
bone sarcomasoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06126510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126510.